Enanta Pharma Analyst Ratings
Enanta Pharma Analyst Ratings
Enanta 製藥分析師評級
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/23/2023 | 226.09% | HC Wainwright & Co. | $48 → $30 | Maintains | Buy |
| 10/02/2023 | 63.04% | RBC Capital | $25 → $15 | Maintains | Sector Perform |
| 09/19/2023 | 421.74% | HC Wainwright & Co. | → $48 | Reiterates | Buy → Buy |
| 08/09/2023 | 171.74% | Oppenheimer | $30 → $25 | Maintains | Perform |
| 08/08/2023 | 421.74% | HC Wainwright & Co. | → $48 | Reiterates | Buy → Buy |
| 08/08/2023 | 171.74% | RBC Capital | → $25 | Reiterates | Sector Perform → Sector Perform |
| 08/08/2023 | 356.52% | JMP Securities | $65 → $42 | Maintains | Market Outperform |
| 08/08/2023 | 95.65% | Jefferies | $49 → $18 | Downgrades | Buy → Hold |
| 05/11/2023 | 226.09% | Oppenheimer | $50 → $30 | Reiterates | Perform → Perform |
| 05/09/2023 | 258.7% | RBC Capital | $48 → $33 | Maintains | Sector Perform |
| 05/09/2023 | 421.74% | HC Wainwright & Co. | $68 → $48 | Maintains | Buy |
| 05/09/2023 | 606.52% | JMP Securities | $82 → $65 | Maintains | Outperform |
| 03/22/2023 | 486.96% | RBC Capital | → $54 | Reiterates | → Sector Perform |
| 02/09/2023 | 432.61% | SVB Leerink | → $49 | Reiterates | → Market Perform |
| 02/08/2023 | 845.65% | Piper Sandler | → $87 | Maintains | Overweight |
| 02/08/2023 | 552.17% | JP Morgan | $74 → $60 | Maintains | Neutral |
| 01/27/2023 | 432.61% | SVB Leerink | $50 → $49 | Maintains | Market Perform |
| 12/09/2022 | 508.7% | HC Wainwright & Co. | → $56 | Initiates Coverage On | → Buy |
| 11/22/2022 | 486.96% | RBC Capital | $65 → $54 | Maintains | Sector Perform |
| 08/10/2022 | 541.3% | Oppenheimer | $53 → $59 | Maintains | Perform |
| 08/09/2022 | 1389.13% | JMP Securities | $103 → $137 | Maintains | Market Outperform |
| 08/09/2022 | 617.39% | RBC Capital | $67 → $66 | Maintains | Sector Perform |
| 08/01/2022 | 476.09% | Oppenheimer | $45 → $53 | Maintains | Perform |
| 08/01/2022 | 443.48% | SVB Leerink | $44 → $50 | Maintains | Market Perform |
| 07/06/2022 | 573.91% | Evercore ISI Group | → $62 | Upgrades | In-Line → Outperform |
| 07/01/2022 | 628.26% | RBC Capital | $64 → $67 | Maintains | Sector Perform |
| 06/01/2022 | 323.91% | Evercore ISI Group | → $39 | Upgrades | Underperform → In-Line |
| 05/20/2022 | 389.13% | Oppenheimer | $70 → $45 | Maintains | Outperform |
| 05/19/2022 | 878.26% | Baird | $130 → $90 | Maintains | Outperform |
| 05/19/2022 | 1019.57% | JMP Securities | $114 → $103 | Maintains | Market Outperform |
| 05/19/2022 | 378.26% | SVB Leerink | $58 → $44 | Maintains | Market Perform |
| 05/12/2022 | 660.87% | Roth Capital | $101 → $70 | Maintains | Buy |
| 05/10/2022 | 1139.13% | JMP Securities | $116 → $114 | Maintains | Market Outperform |
| 05/10/2022 | 530.43% | SVB Leerink | $68 → $58 | Maintains | Market Perform |
| 05/10/2022 | 595.65% | RBC Capital | $72 → $64 | Maintains | Sector Perform |
| 02/09/2022 | 639.13% | SVB Leerink | $80 → $68 | Maintains | Market Perform |
| 01/13/2022 | 769.57% | SVB Leerink | $85 → $80 | Maintains | Market Perform |
| 11/24/2021 | 693.48% | Oppenheimer | $55 → $73 | Maintains | Perform |
| 11/23/2021 | 1160.87% | JMP Securities | $111 → $116 | Maintains | Market Outperform |
| 11/23/2021 | 823.91% | SVB Leerink | $92 → $85 | Maintains | Market Perform |
| 11/19/2021 | 682.61% | RBC Capital | $74 → $72 | Maintains | Sector Perform |
| 11/19/2021 | 1106.52% | JMP Securities | $121 → $111 | Maintains | Market Outperform |
| 11/08/2021 | 1215.22% | JMP Securities | $77 → $121 | Maintains | Market Outperform |
| 11/08/2021 | 900% | SVB Leerink | $55 → $92 | Maintains | Market Perform |
| 10/20/2021 | 704.35% | RBC Capital | $58 → $74 | Maintains | Sector Perform |
| 10/20/2021 | 736.96% | JMP Securities | $73 → $77 | Maintains | Market Outperform |
| 10/07/2021 | 932.61% | Jefferies | → $95 | Initiates Coverage On | → Buy |
| 09/09/2021 | 497.83% | SVB Leerink | → $55 | Initiates Coverage On | → Market Perform |
| 08/09/2021 | 443.48% | RBC Capital | $52 → $50 | Maintains | Sector Perform |
| 08/06/2021 | 443.48% | RBC Capital | $52 → $50 | Maintains | Sector Perform |
| 08/06/2021 | 736.96% | JMP Securities | $70 → $77 | Maintains | Market Outperform |
| 01/29/2021 | 497.83% | JP Morgan | $44 → $55 | Upgrades | Underweight → Neutral |
| 11/24/2020 | 226.09% | Evercore ISI Group | → $30 | Initiates Coverage On | → Underperform |
| 08/28/2020 | 1030.43% | Roth Capital | → $104 | Reinstates | → Buy |
| 08/26/2020 | 845.65% | Piper Sandler | → $87 | Initiates Coverage On | → Overweight |
| 07/27/2020 | 660.87% | JMP Securities | → $70 | Upgrades | Market Perform → Market Outperform |
| 03/17/2020 | 552.17% | Baird | → $60 | Upgrades | Neutral → Outperform |
| 11/22/2019 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 09/26/2019 | 519.57% | JP Morgan | $86 → $57 | Downgrades | Neutral → Underweight |
| 12/13/2018 | 769.57% | Berenberg | → $80 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/23/2023 | 226.09% | HC Wainwright公司 | $48→$30 | 維護 | 買 |
| 10/02/2023 | 63.04% | 加拿大皇家銀行資本 | $25→$15 | 維護 | 行業表現 |
| 2023/09/19 | 421.74% | HC Wainwright公司 | →$48 | 重申 | 購買→購買 |
| 08/09/2023 | 171.74% | 奧本海默 | $30→$25 | 維護 | 執行 |
| 2023/08/08 | 421.74% | HC Wainwright公司 | →$48 | 重申 | 購買→購買 |
| 2023/08/08 | 171.74% | 加拿大皇家銀行資本 | →$25 | 重申 | 扇區表現→扇區表現 |
| 2023/08/08 | 356.52% | JMP證券 | $65→$42 | 維護 | 市場表現強於大盤 |
| 2023/08/08 | 95.65% | 傑富瑞 | $49→$18 | 評級下調 | 購買→Hold |
| 2023年05月11日 | 226.09% | 奧本海默 | $50→$30 | 重申 | 執行→執行 |
| 05/09/2023 | 258.7% | 加拿大皇家銀行資本 | $48→$33 | 維護 | 行業表現 |
| 05/09/2023 | 421.74% | HC Wainwright公司 | $68→$48 | 維護 | 買 |
| 05/09/2023 | 606.52% | JMP證券 | $82→$65 | 維護 | 跑贏大盤 |
| 03/22/2023 | 486.96% | 加拿大皇家銀行資本 | →$54 | 重申 | →行業表現 |
| 02/09/2023 | 432.61% | SVB Leerink | →$49 | 重申 | →市場表現 |
| 02/08/2023 | 845.65% | 派珀·桑德勒 | →$87 | 維護 | 超重 |
| 02/08/2023 | 552.17% | 摩根大通 | $74→$60 | 維護 | 中性 |
| 2023年1月27日 | 432.61% | SVB Leerink | $50→$49 | 維護 | 市場表現 |
| 12/09/2022 | 508.7% | HC Wainwright公司 | →$56 | 開始承保 | →購買 |
| 2022年11月22日 | 486.96% | 加拿大皇家銀行資本 | $65→$54 | 維護 | 行業表現 |
| 2022年08月10日 | 541.3% | 奧本海默 | $53→$59 | 維護 | 執行 |
| 08/09/2022 | 1389.13% | JMP證券 | $103→$137 | 維護 | 市場表現強於大盤 |
| 08/09/2022 | 617.39% | 加拿大皇家銀行資本 | $67→$66 | 維護 | 行業表現 |
| 08/01/2022 | 476.09% | 奧本海默 | $45→$53 | 維護 | 執行 |
| 08/01/2022 | 443.48% | SVB Leerink | $44→$50 | 維護 | 市場表現 |
| 07/06/2022 | 573.91% | Evercore ISI集團 | →$62 | 升級 | 線內→表現優異 |
| 07/01/2022 | 628.26% | 加拿大皇家銀行資本 | $64→$67 | 維護 | 行業表現 |
| 06/01/2022 | 323.91% | Evercore ISI集團 | →$39 | 升級 | 表現不佳的直插式→ |
| 05/20/2022 | 389.13% | 奧本海默 | $70→$45 | 維護 | 跑贏大盤 |
| 2022年05月19日 | 878.26% | 貝爾德 | $130→$90 | 維護 | 跑贏大盤 |
| 2022年05月19日 | 1019.57% | JMP證券 | $114→$103 | 維護 | 市場表現強於大盤 |
| 2022年05月19日 | 378.26% | SVB Leerink | $58→$44 | 維護 | 市場表現 |
| 2022年05月12日 | 660.87% | 羅斯資本 | $101→$70 | 維護 | 買 |
| 2022年05月10日 | 1139.13% | JMP證券 | $116→$114 | 維護 | 市場表現強於大盤 |
| 2022年05月10日 | 530.43% | SVB Leerink | $68→$58 | 維護 | 市場表現 |
| 2022年05月10日 | 595.65% | 加拿大皇家銀行資本 | $72→$64 | 維護 | 行業表現 |
| 02/09/2022 | 639.13% | SVB Leerink | $80→$68 | 維護 | 市場表現 |
| 2022年01月13日 | 769.57% | SVB Leerink | $85→$80 | 維護 | 市場表現 |
| 2021年11月24日 | 693.48% | 奧本海默 | $55→$73 | 維護 | 執行 |
| 2021年11月23日 | 1160.87% | JMP證券 | $111→$116 | 維護 | 市場表現強於大盤 |
| 2021年11月23日 | 823.91% | SVB Leerink | $92→$85 | 維護 | 市場表現 |
| 2021年11月19日 | 682.61% | 加拿大皇家銀行資本 | $74→$72 | 維護 | 行業表現 |
| 2021年11月19日 | 1106.52% | JMP證券 | $121→$111 | 維護 | 市場表現強於大盤 |
| 11/08/2021 | 1215.22% | JMP證券 | $77→$121 | 維護 | 市場表現強於大盤 |
| 11/08/2021 | 900% | SVB Leerink | $55→$92 | 維護 | 市場表現 |
| 10/20/2021 | 704.35% | 加拿大皇家銀行資本 | $58→$74 | 維護 | 行業表現 |
| 10/20/2021 | 736.96% | JMP證券 | $73→$77 | 維護 | 市場表現強於大盤 |
| 10/07/2021 | 932.61% | 傑富瑞 | →$95 | 開始承保 | →購買 |
| 09/09/2021 | 497.83% | SVB Leerink | →$55 | 開始承保 | →市場表現 |
| 08/09/2021 | 443.48% | 加拿大皇家銀行資本 | $52→$50 | 維護 | 行業表現 |
| 08/06/2021 | 443.48% | 加拿大皇家銀行資本 | $52→$50 | 維護 | 行業表現 |
| 08/06/2021 | 736.96% | JMP證券 | $70→$77 | 維護 | 市場表現強於大盤 |
| 2021/01/29 | 497.83% | 摩根大通 | $44→$55 | 升級 | 減重→中性 |
| 11/24/2020 | 226.09% | Evercore ISI集團 | →$30 | 開始承保 | →表現不佳 |
| 2020/08/28 | 1030.43% | 羅斯資本 | →$104 | 恢復 | →購買 |
| 2020/08/26 | 845.65% | 派珀·桑德勒 | →$87 | 開始承保 | →超重 |
| 07/27/2020 | 660.87% | JMP證券 | →$70 | 升級 | 市場表現優於→市場表現 |
| 03/17/2020 | 552.17% | 貝爾德 | →$60 | 升級 | 中性→表現優異 |
| 2019年11月22日 | - | JMP證券 | 評級下調 | 市場表現優於→市場表現 | |
| 2019年09月26日 | 519.57% | 摩根大通 | $86→$57 | 評級下調 | 中性→減持 |
| 2018年12月13日 | 769.57% | 貝倫伯格 | →$80 | 開始承保 | →購買 |
What is the target price for Enanta Pharma (ENTA)?
Enanta Pharma(Enta)的目標價是多少？
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on October 23, 2023. The analyst firm set a price target for $30.00 expecting ENTA to rise to within 12 months (a possible 226.09% upside). 19 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年10月23日報道了Enanta Pharma(納斯達克代碼：ENTA)的最新目標價。這家分析公司將目標價定為30美元，預計Enta將在12個月內上漲(可能上漲226.09)。去年有19家分析公司公佈了評級。
What is the most recent analyst rating for Enanta Pharma (ENTA)?
分析師對Enanta Pharma(Enta)的最新評級是多少？
The latest analyst rating for Enanta Pharma (NASDAQ: ENTA) was provided by HC Wainwright & Co., and Enanta Pharma maintained their buy rating.
分析師對Enanta Pharma(納斯達克代碼：ENTA)的最新評級由HC Wainwright&Co.提供，Enanta Pharma維持買入評級。
When is the next analyst rating going to be posted or updated for Enanta Pharma (ENTA)?
Enanta Pharma(Enta)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enanta Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enanta Pharma was filed on October 23, 2023 so you should expect the next rating to be made available sometime around October 23, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Enanta Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Enanta Pharma的上一次評級是在2023年10月23日提交的，因此您應該預計下一次評級將在2024年10月23日左右的某個時候提供。
Is the Analyst Rating Enanta Pharma (ENTA) correct?
分析師對Enanta Pharma(Enta)的評級正確嗎？
While ratings are subjective and will change, the latest Enanta Pharma (ENTA) rating was a maintained with a price target of $48.00 to $30.00. The current price Enanta Pharma (ENTA) is trading at is $9.20, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Enanta Pharma(Enta)評級維持不變，目標價在48.00美元至30.00美元之間。Enanta Pharma(Enta)目前的交易價格為9.20美元，超出了分析師的預測區間。